Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK® in autoimmune disease. The article discusses the company’s planned Phase 3 trial in refractory rheumatoid arthritis and its focus on developing an outpatient-ready, scalable approach to deep B-cell depletion. Read the article here (subscription may…
Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated. In this episode of the Biotech2050 podcast, Artiva’s CEO Fred Aslan discusses how lessons from the first generation of CAR-T therapies are shaping new approaches in autoimmune…
In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents. In a this episode of the 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Lisa Guerrettaz, Executive Director, Pharmacology and Translational Science at Artiva Biotherapeutics, discusses how the limitations of currently approved treatments are driving the development…
SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease Artiva Biotherapeutics was featured in the San Diego Business Journal highlighting the Company’s strategic transition into autoimmune disease and the FDA Fast Track Designation for AlloNK® in rheumatoid arthritis. The story outlines how AlloNK is designed for outpatient use and underscores the significant…
Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials…
In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more…
In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and…
NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t…
Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo. In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Read the full article here (subscription may be required).
DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer,…